MannKind (MNKD) Stock Forecast & Price Target

MannKind is attractive because its thesis is increasingly supported by durable royalty and collaboration revenue, visible momentum in Afrezza, and multiple catalysts that can re-rate the story without relying on a single asset. The company reported 1Q26 revenue of $90.2M versus FactSet consensus of $105.4M, non-GAAP EPS of $(0.02), and ended the quarter with $134M of cash and investments after settling senior convertible notes, while management reiterated 2026 FUROSCIX revenue of $110M to $120M. Beyond that, the underappreciated IPF portfolio is strengthening through Tyvaso DPI, ralinepag DPI, and MNKD-201, while ReadyFlow and the Afrezza pediatric PDUFA provide near-term commercial and regulatory upside.

MannKind is facing a fundamentally challenged outlook because its revenue base depends heavily on internal products and partnered assets that may undershoot expectations, limiting its ability to fund the pipeline and reach profitability without additional capital. The company also faces meaningful regulatory and clinical risk for its U.S. and European programs, while competition from cheaper alternatives could pressure uptake and margins. Although Tyvaso DPI and ralinepag DPI create upside, MannKind remains dependent on United Therapeutics’ execution and on royalty revenue that consensus expects to decline from 2027 onward.